A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ±
Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma